Free Trial

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie logo
$210.33 +0.83 (+0.40%)
As of 03:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbbVie - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
6
Buy
21

Based on 27 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 6 have given a hold rating, 16 have given a buy rating, and 5 have given a strong buy rating for ABBV.

Consensus Price Target

$214.95
2.20% Upside
According to the 27 analysts' twelve-month price targets for AbbVie, the average price target is $214.95. The highest price target for ABBV is $255.00, while the lowest price target for ABBV is $190.00. The average price target represents a forecasted upside of 2.20% from the current price of $210.33.
Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

Sign Up

ABBV Analyst Ratings Over Time

TypeCurrent Forecast
8/22/24 to 8/22/25
1 Month Ago
7/23/24 to 7/23/25
3 Months Ago
5/24/24 to 5/24/25
1 Year Ago
8/23/23 to 8/22/24
Strong Buy
5 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
16 Buy rating(s)
17 Buy rating(s)
13 Buy rating(s)
Hold
6 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$214.95$211.29$210.95$190.29
Forecasted Upside2.20% Upside11.00% Upside14.96% Upside-3.10% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbbVie Stock vs. The Competition

TypeAbbVieMedical CompaniesS&P 500
Consensus Rating Score
2.96
2.79
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.58% Upside12,759.70% Upside11.95% Upside
News Sentiment Rating
Positive News

See Recent ABBV News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/12/2025Piper Sandler
2 of 5 stars
David Amsellem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$231.00+16.40%
8/7/2025Daiwa America
0 of 5 stars
 UpgradeHold ➝ Strong-Buy
8/7/2025Daiwa Capital Markets
2 of 5 stars
 UpgradeNeutral ➝ Outperform$214.00+8.98%
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Terence Flynn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$250.00 ➝ $255.00+31.75%
8/1/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vamil Divan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$216.00 ➝ $227.00+17.28%
8/1/2025Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gary Nachman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$227.00 ➝ $236.00+24.85%
6/11/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold$205.00+7.09%
6/9/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$204.00+7.43%
5/8/2025BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Ty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/28/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gavin Clark-Gartner
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$204.00 ➝ $205.00+8.82%
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$210.00+23.52%
4/8/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Neutral$194.00+5.94%
3/17/2025Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
H. Engel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/5/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$210.00 ➝ $240.00+15.11%
2/3/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Srikripa Devarakonda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$211.00 ➝ $217.00+14.50%
2/3/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Navin Jacob
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$181.00 ➝ $190.00+0.71%
2/3/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Evan David Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$208.00 ➝ $215.00+16.91%
12/17/2024Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$220.00+25.13%
11/22/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/22/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$206.00+19.64%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$205.00+20.85%
11/13/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$210.00 ➝ $200.00+16.74%
11/4/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$203.00+6.58%
10/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$200.00 ➝ $212.00+9.75%
10/7/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$195.00 ➝ $225.00+16.22%
8/30/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/5/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$185.00+14.08%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$150.00+5.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:33 PM ET.


Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 21, 2025. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AbbVie:

  • AbbVie has received multiple upgrades from analysts, with a consensus target price of approximately $214.95, indicating potential for growth.
  • The current stock price is around $208.72, which is close to the analysts' target, suggesting it may be a good entry point for investors.
  • Five analysts have rated AbbVie with a Strong Buy rating, reflecting strong confidence in the company's future performance.
  • AbbVie has a solid market capitalization of approximately $368.72 billion, indicating a stable and established presence in the pharmaceutical industry.
  • The company has a low beta of 0.50, suggesting that its stock is less volatile compared to the overall market, which can be appealing for risk-averse investors.

AbbVie
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AbbVie for these reasons:

  • AbbVie has a high price-to-earnings (P/E) ratio of 99.39, which may indicate that the stock is overvalued compared to its earnings.
  • The company has a debt-to-equity ratio of 44.14, suggesting a significant amount of debt relative to its equity, which could pose risks in economic downturns.
  • Recent insider selling, including significant transactions by executives, may raise concerns about the company's future prospects and management confidence.
  • AbbVie has a quick ratio of 0.61, indicating potential liquidity issues, as it may not have enough short-term assets to cover its short-term liabilities.
  • The stock has experienced fluctuations, with a 52-week low of $163.81, which may indicate volatility and uncertainty in its performance.

ABBV Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $214.95, with a high forecast of $255.00 and a low forecast of $190.00.

27 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 6 hold ratings, 16 buy ratings and 5 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABBV shares.

According to analysts, AbbVie's stock has a predicted upside of 2.20% based on their 12-month stock forecasts.

Over the previous 90 days, AbbVie's stock had 3 upgrades by analysts.

AbbVie has been rated by research analysts at Bank of America, Citigroup, Daiwa America, Daiwa Capital Markets, Guggenheim, Morgan Stanley, Piper Sandler, and Raymond James Financial in the past 90 days.

Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.96 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ABBV compares to other companies.


This page (NYSE:ABBV) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners